Page 120 - 《中国药房》2024年12期

卡瑞利珠单抗联合索拉非尼治疗晚期肝癌的临床观察
Δ

邹瑜斌 ，杨 灵，肖池金（新余市人民医院肿瘤科，江西 新余 338025）
＊

中图分类号 R979.1 文献标志码 A 文章编号 1001-0408（2024）12-1522-05
DOI 10.6039/j.issn.1001-0408.2024.12.19

摘 要 目的 观察卡瑞利珠单抗联合索拉非尼治疗晚期肝癌的临床疗效和安全性。方法 选择我院2020年3月－2021年11月
收治的60例晚期肝癌患者，将其按随机数字表法分为研究组和对照组，每组各30例。对照组患者给予甲苯磺酸索拉非尼片（0.4
g，bid，口服），研究组患者在对照组用药的基础上给予注射用卡瑞利珠单抗（200 mg，每3周1次，静脉滴注），所有患者均治疗至疾
病进展或发生不可耐受的副反应时停止治疗。比较两组患者的临床疗效、无进展生存期（PFS）、总生存期（OS）、1年生存率，记录
两组患者治疗期间的不良反应及研究组患者的免疫相关不良事件发生情况。结果 研究组患者的客观缓解率显著高于对照组
（36.7%vs 13.3%，P＜0.05），中位OS和中位PFS均显著长于对照组（OS：12.6个月 vs 7.9个月；PFS：8.2个月 vs 5.3个月，P＜0.05）。
两组患者的1年生存率及天冬氨酸转氨酶和丙氨酸转氨酶升高、皮疹或皮肤瘙痒、食欲减退、腹泻、乏力、高血压发生率比较，差异
均无统计学意义（P＞0.05）。研究组患者发生的免疫治疗相关不良事件主要包括反应性毛细血管增生症21例（70.0%）、甲状腺功
能减退6例（20.0%）、免疫相关性肺炎1例（3.3%），经对症治疗后均有所好转或可耐受。结论 卡瑞利珠单抗联合索拉非尼可有效
控制和延缓晚期肝癌患者的病情进展，延长患者生存时间，且不良反应可耐受。
关键词 索拉非尼；卡瑞利珠单抗；肝癌；晚期；生存期；疗效；安全性

Clinical observation of camrelizumab combined with sorafenib in the treatment of advanced liver cancer
ZOU Yubin，YANG Ling，XIAO Chijin（Dept. of Oncology， Xinyu People’s Hospital， Jiangxi Xinyu 338025，
China）

ABSTRACT OBJECTIVE To observe the clinical efficacy and safety of camrelizumab combined with sorafenib in the treatment
of advanced liver cancer. METHODS Sixty patients with advanced liver cancer who were treated in our hospital from March 2020
to November 2021 were selected as the study subjects， and then were randomly divided into study group and control group， with
30 cases in each group. The control group was treated with Sorafenib tosylate tablets orally （0.4 g，bid）， and the study group was
additionally given Camrelizumab for injection intravenously （200 mg， every 3 weeks） based on the control group； for all patients，
the treatment was stopped until disease progression or intolerable side effects occurred. The clinical efficacy， progression-free
survival （PFS）， total survival （OS） and 1-year survival rate of the two groups were compared， and the incidence of adverse
reactions in two groups， and immune-related adverse reactions in the study group during treatment were recorded. RESULTS The
objective remission rate of the study group was significantly higher than the control group （36.7% vs. 13.3%， P＜0.05）， and the
median OS and median PFS were significantly longer than the control group （OS： 12.6 months vs. 7.9 months； PFS： 8.2 months
vs. 5.3 months， P＜0.05）. There was no significant difference in the 1-year survival rate and the incidence of elevated aspartate
aminotransferase and alanine aminotransferase， rash or pruritus， anorexia， diarrhea， fatigue and hypertension between the two
groups （P＞0.05）. The adverse events immune-related in the study group mainly included 21 cases of reactive capillary hyperplasia
（70.0%）， 6 cases of hypothyroidism （20.0%）， and 1 case of immune-associated pneumonia （3.3%）， which were improved or
tolerable after symptomatic treatment. CONCLUSIONS Camrelizumab combined with sorafenib in the treatment of advanced liver
cancer can effectively control and delay the disease progression， prolong the survival period of patients， and the adverse reactions
can be tolerated.
KEYWORDS sorafenib； camrelizumab； liver cancer； advanced； survival period； therapeutic effect； safety

肝癌是临床常见的消化系统恶性肿瘤之一。近年
Δ 基金项目 江西省卫生健康委科技计划项目（No.202140597）
来，我国肝癌发病率呈现上升趋势，其发病率仅次于胃
＊第一作者 主任医师，硕士。研究方向：肿瘤综合治疗。电话：
[1]
0790-6652070。E-mail：tj885621@163.com 癌、肠癌及食道癌等消化系统恶性肿瘤 。分子靶向药

· 1522 · China Pharmacy 2024 Vol. 35 No. 12 中国药房 2024年第35卷第12期